[go: up one dir, main page]

PE20030541A1 - Compuestos pirimidina de anillo fusionado alquinilado como inhibidores de metaloproteasa de matriz tipo 13 - Google Patents

Compuestos pirimidina de anillo fusionado alquinilado como inhibidores de metaloproteasa de matriz tipo 13

Info

Publication number
PE20030541A1
PE20030541A1 PE2002001007A PE2002001007A PE20030541A1 PE 20030541 A1 PE20030541 A1 PE 20030541A1 PE 2002001007 A PE2002001007 A PE 2002001007A PE 2002001007 A PE2002001007 A PE 2002001007A PE 20030541 A1 PE20030541 A1 PE 20030541A1
Authority
PE
Peru
Prior art keywords
alkyl
methyl
compounds
quinazolin
dioxo
Prior art date
Application number
PE2002001007A
Other languages
English (en)
Inventor
Picard Joseph Armand
Wilson Michael William
Henry Jacobelli
Bernard Gaudilliere
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2001/011824 external-priority patent/WO2003033477A1/en
Priority claimed from PCT/EP2002/008475 external-priority patent/WO2004007469A1/en
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20030541A1 publication Critical patent/PE20030541A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS DE PIRIMIDINA DE ANILLO FUSIONADO ALQUINILADO DE FORMULA I DONDE W1 ES O, S, NR3; R3 ES H, ALQUILO, OH, CN; W2 ES H, CF3, NH2, ALQUILO, ALQUENILO, ALQUINILO, ARILO, ENTRE OTROS; W1 O W2 JUNTOS FORMAN N-X4=W3-; W3 ES N, CR5; R5 ES H, OR6, SR6; R6 ES H, ALQUILO, ARILALQUILO; X4 ES N, CR7; R7 ES H, NR8R9, OR8, SR8, ALQUILO, CICLOALQUILO, ENTRE OTROS; X1, X2, X3 SON N, CARBONO OPCIONALMENTE SUSTITUIDO CON ALQUILO, S(O)n1R4, NR10R11; n1 ES 0-2; R4 ES H, ALQUILO; R10 Y NO MAS DE 2 X1, X2, X3 SON A LA VEZ N; n ES 0-8;: Z ES CR12R13; R12 Y R13 SON H, ALQUILO, TRIHALOGENOALQUILO, HALOGENO, AMINO, ENTRE OTROS; A ES ARILO, HETEROARILO, CICLOALQUILO, HETEROCICLOALQUILO; R2 ES H, ALQUILO, HALOGENO, CIANO, NITRO, ENTRE OTROS; Q ES 0-7; R1 ES H, ALQUILO, ALQUENILO, ALQUINILO; SON COMPUESTOS PREFERIDOS METIL 4-{6-[3-(4-METOXIFENIL)-PROP-1-INIL]-1-METIL-2,4-DIOXO-1,4-DIHIDRO-2H-QUINAZOLIN-3-ILMETIL}-BENZOATO; ACIDO 4-[1-METIL-2,4-DIOXO-6-(3-FENIL-PROP-1-INIL)-1,4-DIHIDRO-2H-QUINAZOLIN-3-ILMETIL]-BENZOICO; ACIDO 4-{6-[3-(4-METOXI-FENIL)-PROP-1-INIL)-1-METIL-2,4-DIOXO-1,4-DIHIDRO-2H-QUINAZOLIN-3-ILMETIL]-BENZOICO; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION Y A COMPUESTOS INTERMEDIOS. LOS COMPUESTOS SON INHIBIDORES DE METALOPROTEASA DE MATRIZ TIPO 13 Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE ARTRITIS, ARTRITIS REUMATOIDEA, OSTEOARTRITIS, OSTEOPOROSIS, ENFERMEDADES PERIODONTALES, ENFERMEDAD INTESTINAL INFLAMATORIA
PE2002001007A 2001-10-12 2002-10-11 Compuestos pirimidina de anillo fusionado alquinilado como inhibidores de metaloproteasa de matriz tipo 13 PE20030541A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2001/011824 WO2003033477A1 (en) 2001-10-12 2001-10-12 Alkynlated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitor
PCT/EP2002/008475 WO2004007469A1 (en) 2002-07-12 2002-07-12 New alkynylated quinazolin compounds as mmp-13 inhibitors

Publications (1)

Publication Number Publication Date
PE20030541A1 true PE20030541A1 (es) 2003-08-13

Family

ID=26069227

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001007A PE20030541A1 (es) 2001-10-12 2002-10-11 Compuestos pirimidina de anillo fusionado alquinilado como inhibidores de metaloproteasa de matriz tipo 13

Country Status (11)

Country Link
US (1) US20050245548A1 (es)
JP (1) JP2005509626A (es)
AR (1) AR037100A1 (es)
BR (1) BR0213239A (es)
CA (1) CA2463159A1 (es)
MX (1) MXPA04003008A (es)
PA (1) PA8556301A1 (es)
PE (1) PE20030541A1 (es)
SV (1) SV2003001289A (es)
UY (1) UY27485A1 (es)
WO (1) WO2003033478A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040260108A1 (en) * 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
CA2462442A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
JP2006502991A (ja) * 2002-07-17 2006-01-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ−１３のアロステリックアルキン阻害剤とセレコキシブまたはバルデコキシブではないシクロオキシゲナーゼ−２の選択的阻害剤との組合せ物
EP1534274A1 (en) * 2002-07-17 2005-06-01 Warner-Lambert Company LLC Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
AU2003250465A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 5,6-fused uracil derivatives as matrix metalloproteinase inhibitors
WO2004014375A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
WO2004014378A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
JP2006501215A (ja) 2002-08-13 2006-01-12 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体
CA2497658A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
EP1539709A1 (en) 2002-08-13 2005-06-15 Warner-Lambert Company LLC Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004014923A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014868A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
WO2005019188A1 (ja) * 2003-08-22 2005-03-03 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
DE10360835A1 (de) * 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
CN106146413B (zh) * 2015-04-03 2019-01-18 中南大学 2,4-(1h,3h)-喹唑啉二酮衍生物及其合成方法和用途
CN119192133A (zh) 2020-08-12 2024-12-27 基因泰克公司 喹唑啉化合物之合成
CN112107602B (zh) * 2020-09-08 2021-10-15 中国科学院烟台海岸带研究所 一对含双氮生物碱对映体及其制备和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902796A (en) * 1986-10-20 1990-02-20 The Trustees Of Princeton University 6-alkenyl and ethynyl derivatives of 2-amino-4-hydroxypyrido[2,3-d]pyrimidines
US4818819A (en) * 1986-10-20 1989-04-04 The Trustees Of Princeton University Process for the preparation of fused pyridine compounds
US5608082A (en) * 1994-07-28 1997-03-04 Agouron Pharmaceuticals, Inc. Compounds useful as antiproliferative agents and GARFT inhibitors
JPH10195063A (ja) * 1996-10-21 1998-07-28 Dai Ichi Seiyaku Co Ltd エチニルチアゾール誘導体
AU5380398A (en) * 1996-12-17 1998-07-15 E.I. Du Pont De Nemours And Company Fungicidal quinazolinones
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz

Also Published As

Publication number Publication date
US20050245548A1 (en) 2005-11-03
SV2003001289A (es) 2003-06-24
MXPA04003008A (es) 2004-07-16
WO2003033478A1 (en) 2003-04-24
JP2005509626A (ja) 2005-04-14
AR037100A1 (es) 2004-10-20
BR0213239A (pt) 2004-09-28
PA8556301A1 (es) 2003-09-05
CA2463159A1 (en) 2003-04-24
UY27485A1 (es) 2003-05-30

Similar Documents

Publication Publication Date Title
PE20030541A1 (es) Compuestos pirimidina de anillo fusionado alquinilado como inhibidores de metaloproteasa de matriz tipo 13
PE20050132A1 (es) Piperazinas heterociclicas sustituidas
PE20081316A1 (es) COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
PE20060243A1 (es) Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina
CY1107244T1 (el) Μιμητικα γλυκοκορτικοειδων, μεθοδοι παρασκευης τους, φαρμακευτικες συνθεσεις και χρησεις τους
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
CY1108841T1 (el) Υποκατεστημενες με φθοριο κυκλοαλκανοϊνδολες και η χρηση τους ως ανταγωνιστες των υποδοχεων προσταγλανδινης d2
EA200500304A1 (ru) Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний
PE20040590A1 (es) Composiciones de pirrolotriazina anilina como inhibidores de cinasa
PA8581401A1 (es) Compuestos de imedazopiridina como agonistas del receptor 5-ht4
CY1108908T1 (el) Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4
ES2174757A1 (es) Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.
DK1856045T3 (da) 1-eddikesyreindolderviater med PGD2-antagonisteffekt
JP5087171B2 (ja) ５−ヒドロキシトリプタミン−６リガンドとしての１−（アリールスルホニル）−４−（ピペラジン−１−イル）−１ｈ−ベンズイミダゾール類
PE20060736A1 (es) DERIVADOS DE PIRROL COMO ANTAGONISTAS DE CRTh2
PE20091243A1 (es) Compuesto heterociclico fusionado
RU2006146632A (ru) Производные хиназолинона, полезные в качестве ванилоидных антагонистов
PE20040698A1 (es) Derivados de isoindolina
PE20051171A1 (es) Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo
RU2004113111A (ru) Производные индола в качестве ингибиторов сох 11
PE20030726A1 (es) 4-feniltetrahidroisoquinolinas sustituidas, proceso para su preparacion y composiciones farmaceuticas que las contienen
EA200801001A1 (ru) Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине
PE20030707A1 (es) Agonistas muscarinicos
PE20030037A1 (es) Derivados de cianoantranilamida como inhibidores de la tirosina cinasa
PE20010153A1 (es) Derivados de 4-fenil-pirimidina como antagonistas del receptor de neuroquinina

Legal Events

Date Code Title Description
FD Application declared void or lapsed